Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets CAMBRIDGE, England – Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive, Steve will guide the expansion of … Continue reading Broken String Biosciences Appoints Steve Becker as Chief Commercial Officer

Expansion of the Board and the company’s recent FDA Clearance marks the beginning of Orthobond’s commercialization phase PRINCETON, N.J. – Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, today publicly announced the appointment of Eric Major as the company’s Chairman of the Board. “We are pleased to be expanding Orthobond’s Board of Directors with the appointment … Continue reading Orthobond Expands its Board of Directors with Appointment of Eric Major as Chairman

VIENNA, Va. – CEL-SCI Corporation (NYSE American: CVM) today announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to … Continue reading CEL-SCI Appoints Robert Watson as Chairperson of the Board

Acquisition provides Ligand with the royalty rights to QARZIBA®, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A. QARZIBA is the sixth key asset added to Ligand’s commercial stage portfolio since the beginning of 2023 Transaction will be immediately accretive to Ligand EPS by an estimated $1.00 per share on an annualized basis with a $0.50 impact to … Continue reading Ligand to Acquire APEIRON Biologics AG for $100 Million

SANTA CLARA, Calif. – Agilent Technologies, Inc. (NYSE: A) today announced Bret DiMarco has been named to lead the company’s global legal organization as senior vice president and chief legal officer, as well as serving as secretary. He begins his new role with Agilent effective today. “Bret DiMarco is another outstanding addition to the Agilent leadership team,” said Padraig McDonnell, Agilent president and CEO. “Bret’s … Continue reading Agilent Names Bret DiMarco Chief Legal Officer

Industry Veteran Paul Davie Joins X-Chem Executive Team to Lead Strategic Growth and Partnerships WALTHAM, Mass. – Small molecule drug discovery acceleration experts and DNA-encoded library (DEL) technology pioneers X-Chem, Inc. welcomes Paul Davie as Chief Business Officer. He will lead global business development, focusing on the creation of new market opportunities for the company’s innovative technology platform and shaping new business ventures, collaborations and strategic partnerships to maximize the … Continue reading X-Chem Strengthens Its Data-Driven Discovery Services With New CBO Appointment